12 August 2013 |
AIM: RENE |
ReNeuron Group plc
(the "Company")
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
1. Identity of the issuer or the underlying issuer |
RENEURON GROUP PLC |
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
√ |
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
An event changing the breakdown of voting rights |
|
|||
Other (please specify): |
|
|
||
3. Full name of person(s) subject to the |
The Wales Life Sciences Investment Fund LP
|
|||
4. Full name of shareholder(s) |
-
|
|||
5. Date of the transaction and date on |
9 August 2013 |
|||
6. Date on which issuer notified: |
9 August 2013 |
|||
7. Threshold(s) that is/are crossed or |
From 3% to 11% |
|||
8. Notified details: |
|||||||||||||||
A: Voting rights attached to shares |
|||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
|||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights |
|||||||||||
|
Direct |
Indirect |
Direct |
Indirect |
|||||||||||
ORDINARY SHARES of 1 pence each |
0 |
0 |
200,000,000 |
200,000,000 |
|
11.18% |
|
||||||||
|
|||||||||||||||
B: Qualifying Financial Instruments |
|||||||||||||||
Resulting situation after the triggering transaction |
|||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
|||||||||||
|
|
|
|
|
|||||||||||
|
|||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments |
|||||||||||||||
Resulting situation after the triggering transaction |
|||||||||||||||
Type of financial |
Exercise price |
Expiration date |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights
|
||||||||||
|
|
|
|
|
Nominal |
Delta |
|||||||||
|
|
||||||||||||||
|
|||||||||||||||
Total (A+B+C) |
|||||||||||||||
Number of voting rights |
Percentage of voting rights |
||||||||||||||
200,000,000 |
11.18% |
||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
||
|
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
N/A |
|
11. Number of voting rights proxy holder will cease |
N/A |
|
12. Date on which proxy holder will cease to hold |
N/A |
|
|
||
|
Position calculated on issued capital of 1,788,827,700 (Placement by company on 09 August 2013 of 1,014,000,000 new Ordinary shares). Purchase of 200,000,000 shares by The Wales Life Sciences Investment Fund LP on 09 August 2013
|
|
14. Contact name: |
Shafia Zahoor
|
|
15. Contact telephone number: |
020-7887-7646
|
|